🔗 Share this article

While the United States undertakes historic changes to its immunization guidelines, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about COVID-19 vaccinations throughout the global health crisis and has concentrated on alleged deaths after COVID-19 immunization in her recent position at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Program

Health officials were set to announce radical changes to the childhood immunization program recently, aligning the US with Denmark’s national calendar, it is understood – a major change that would place the US out of step with many the international standard with insufficient data for improved outcomes. This reveal has been delayed until the next year.

Rather than the top vaccines chief, Høeg is scheduled to address the audience at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

A Shift at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for halting certain childhood immunization guidelines in the US so as to align more like Denmark, a nation with nationalized medicine and a population about the size of Wisconsin’s.

To date comments, she has kept her attention on vaccines – typically the purview of Prasad, head of the FDA’s CBER – rather than medication approval.

Concerns Over Expertise

Dr. Høeg has little discernible track record in drug development, oversight or management, which has been standard for previous heads of the CBER. She has worked at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a large organization. She lacks background in drug approvals.”

Past heads of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that previous people who ran the center have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner stated.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office clears numerous off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and so forth, and all of those must be looked after,” Woodcock noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a major management element to the role, which manages over 5,000 staff members. “It is a enormous administrative position, if you execute it properly,” Woodcock said.

Response and Disputed Policies

Regarding concerns about Høeg’s credentials and whether this selection represents increased cooperation among FDA leaders on immunizations, a spokesperson said that the “questions are based on flawed premises”.

“Her resume is consistent with the responsibilities of her position,” the official said, citing the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed one-day medication authorization process that allegedly troubled her predecessors. “How are these medications being chosen for this fast-track system? Who makes the choices?” Howard questioned. “There is a lot of secrecy going on at the regulatory body right now.”

In general, he remarked, “the agency seems to be moving towards laxer rules of all drugs, aside from immunizations.”

Public Track Record on Immunizations

Regarding immunizations, Høeg has a clearer, if concerning, track record, some experts observe. She published a analysis using non-validated crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the current government included changing guidelines for new vaccines and ending “optional” immunizations, she stated after the election on a audio program. At the agency, Dr. Høeg has according to sources suggested excluding adolescent males from receiving Covid vaccines.

“She is an complete ideologue who starts off with her beliefs and reverse-engineers to accommodate the science in a very deceptive, untruthful way,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|